Related Experiment Videos
Increased release of platelet-derived growth factor from platelets in chronic liver disease
T Shiraishi1, S Morimoto, E Koh
1Department of Geriatric Medicine, Osaka University Medical School.
Insights
Patients with chronic liver disease release more platelet-derived growth factor (PDGF) per platelet than healthy individuals. This increased PDGF release correlates with disease severity, suggesting a role in liver pathology.
Area of Science:
- Hepatology
- Hematology
- Biochemistry
Background:
- Chronic liver disease impacts platelet count and function.
- Platelet-derived growth factor (PDGF) is crucial for tissue repair but its role in chronic liver disease is not fully understood.
- Investigating PDGF release from platelets in chronic liver disease patients is important for understanding disease mechanisms.
Purpose of the Study:
- To compare serum platelet-derived growth factor (PDGF) concentrations between healthy controls and patients with chronic liver disease.
- To determine the amount of PDGF released per platelet in patients with chronic liver disease compared to controls.
- To explore the correlation between PDGF release and markers of liver disease severity.
Main Methods:
- Measured serum and plasma concentrations of PDGF in 7 healthy controls and 10 patients with chronic liver disease.
- Quantified peripheral blood platelet counts in all subjects.
- Calculated PDGF released per 10^9 platelets and correlated it with serum pseudocholinesterase activity and indocyanine green retention.
Main Results:
- Plasma PDGF was below detection limits in all subjects.
- Patients with chronic liver disease had significantly lower platelet counts but a higher amount of PDGF released per 10^9 platelets compared to controls.
- Increased PDGF release per platelet inversely correlated with pseudocholinesterase activity and positively with indocyanine green retention, indicating a link to disease severity.
Conclusions:
- Platelets in patients with chronic liver disease release significantly more PDGF per platelet than those in healthy individuals.
- The enhanced PDGF release from platelets in chronic liver disease patients correlates with disease severity.
- These findings suggest a potential role for increased platelet-derived growth factor in the pathogenesis of chronic liver disease.
Abstract:
The concentrations of platelet-derived growth factor in serum in 7 healthy controls (61 +/- 9 years; mean +/- SD) and 10 patients (62 +/- 8 years) with chronic liver disease (chronic hepatitis and/or liver cirrhosis) were compared. The plasma concentration of platelet-derived growth factor was below the detection limit (< 0.45 microgram/l) in all the subjects studied. The peripheral blood platelet count in patients with chronic liver disease was significantly lower than that in control subjects. However, the concentration of platelet-derived growth factor in serum, which was assumed to be released from platelet, was similar in patients with chronic liver disease and control subjects. These results indicate that the mean amount of platelet-derived growth factor released from the same number (10(9)) of platelets, calculated from the serum platelet-derived growth factor concentration and the peripheral blood platelet count, in patients with chronic liver disease (33 +/- 11 ng/10(9) platelets) was significantly (p < 0.01) higher than that in control subjects (14 +/- 5 ng/10(9) platelets). Moreover, the amount of platelet-derived growth factor released from 10(9) platelets inversely correlated with the serum concentration of pseudocholinesterase activity (r = -0.65, p < 0.01), and correlated positively (r = 0.91, p < 0.01) with the percent retention of indocyanine green in serum, in all subjects studied. These findings suggest that the amount of platelet-derived growth factor releasable from platelets of patients with chronic liver disease is higher than that in normal subjects and that it correlates with the severity of the disease.(ABSTRACT TRUNCATED AT 250 WORDS)